Count | |
| 1 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 4 | |
Vinblastine/adverse effects/analogs & derivatives/*therapeutic use | 1 |
Vinblastine/adverse effects/*analogs & derivatives/pharmacology | 1 |
Vinblastine/adverse effects/analogs & derivatives/therapeutic use | 1 |
Vinblastine/administration & dosage/adverse effects/analogs & derivatives | 1 |
Vinblastine/administration & dosage/adverse effects/*analogs & derivative | 1 |
| 3 | |
| 6 | |
| 3 | |
| 6 | |
| 37 | |
| 1 | |
| 1 | |
| 3 | |
| 7 | |
| 4 | |
| 41 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 3 | |
| 4 | |
Vinblastine/*analogs & derivatives/pharmacokinetics/pharmacology | 1 |
| 2 | |
| 6 | |
| 6 | |
Arginine/adverse effects/*analogs & derivatives/blood/*drug effects | 1 |
Phosphoproteins/adverse effects/*antagonists & inhibitors/drug effects | 1 |
C-Reactive Protein/adverse effects/*drug effects/*metabolism | 1 |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 5 | |
| 14 | |
| 1 | |
| 3 | |
| 4 | |
| 11 | |
| 1 | |
| 6 | |
| 1 | |
| 1 | |
| 2 | |
| 3 | |
| 2 | |
| 1 | |
| 3 | |
| 2 | |
| 2 | |
| 1 | |
| 1 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 4 | |
| 1 | |
| 2 | |
| 1 | |
| 3 | |
| 1 | |
| 2 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |